Phase II trial of neoadjuvant temozolomide in resectable melanoma patients

Annals of Oncology

Volumn 21, Issue 8, 2010, Pages 1718-1722

  Shah, G D ^a   Socci, N D ^a   Gold, J S ^c,d   Wolchok, J D ^a   Carvajal, R D ^a   Panageas, K S ^a   Viale, A ^b   Brady, M S ^a   Coit, D G ^a   Chapman, P B ^a  

^a The Computational Biology Center ^*  (United States)

^b The Genomics Core Laboratory   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

MGMT; Microarray

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DNA METHYLATION; DRUG RESPONSE; FATIGUE; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; INTERNATIONAL NORMALIZED RATIO; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MELANOMA; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROMOTER REGION; SIDE EFFECT; SKIN BIOPSY;

EID: 77955249187     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp593     Document Type: Article

References (16)

1. Middleton MR, Grob JJ, Aaronson N et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158-166.
2. Rietschel P, Wolchok JD, Krown S et al. Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol 2008; 26: 2299-2304.
3. 6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008; 10: 332-337.
4. Buzaid AC, Colome M, Bedikian A et al. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Res 1998; 8: 549-556.
5. Gibbs P, Iannucci A, Becker M et al. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma. Melanoma Res 2000; 10: 171-179.
6. Legha SS, Ring S, Eton O et al. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience. Cancer J Sci Am 1997; 3 (Suppl 1): S9-S15.
7. Eton O, Legha SS, Bedikian AY et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002; 20: 2045-2052.
8. Moschos SJ, Edington HD, Land SR et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006; 24: 3164-3171.
9. Dorval T, Palangie T, Jouve M et al. Clinical phase II trial of recombinant DNA interferon (interferon alfa 2b) in patients with metastatic malignant melanoma. Cancer 1986; 58: 215-218.
10. Robinson WA, Mughai TI, Thomas MR. Treatment of metastatic malignant melanoma with recombinant interferon alpha-2. Immunobiology 1986; 172: 275-282.
11. Sertoli MR, Bernengo MG, Ardizzoni A et al. Phase II trial of recombinant alpha-2b interferon in the treatment of metastatic skin melanoma. Oncology 1989; 46: 96-98.
12. Kirkwood JM, Ernstoff MS, Davis CA et al. Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med 1985; 103: 32-36.
13. Paz MF, Yaya-Tur R, Rojas-Marcos I et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004; 10: 4933-4938.
14. Hegi ME, Diserens A-C, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
15. 6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma. Br J Cancer 2003; 89: 1517-1523.
16. 6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer 1998; 78: 1199-1202.